Structure-based inhibitor design by using protein models for the development of antiparasitic agents.

AUTOR(ES)

Ring, C S

RESUMO

The lack of an experimentally determined structure of a target protein frequently limits the application of structure-based drug design methods. In an effort to overcome this limitation, we have investigated the use of computer model-built structures for the identification of previously unknown inhibitors of enzymes from two major protease families, serine and cysteine proteases. We have successfully used our model-built structures to identify computationally and to confirm experimentally the activity of nonpeptidic inhibitors directed against important enzymes in the schistosome [2-(4-methoxybenzoyl)-1-naphthoic acid, Ki = 3 microM] and malaria (oxalic bis[(2-hydroxy-1-naphthylmethylene)hydrazide], IC50 = 6 microM) parasite life cycles.

Documentos Relacionados

• Protein structure-based design of anti-protozoal drugs
• Seeking novel leads through structure-based pharmacophore design
• Structure-based design of a dimeric RNA–peptide complex
• Structure-based design of an RNA-binding zinc finger
• Analysis of homeodomain function by structure-based design of a transcription factor.